To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

CarMollNat Muscular Dystrophy Endowment

Carol-Ann Harris has established the CarMollNat Endowment in memory of her beloved family members. The Endowment is committed to support research and science for the major forms of Muscular Dystrophy (MD) and neurogenetic disease.

11th International Forum on Rheumatoid Arthritis (IFRA)

The 11th International Forum on Rheumatoid Arthritis: Pathogenesis and Emerging Therapeutic Strategies (IFRA 2019) is designed to bring together leading rheumatologists from Europe, the United States and Asian countries working to better understand the pathogenesis and emerging therapeutic strategies in rheumatoid arthritis (RA).

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

Accelerating Medicines Partnership - Alzheimer's Disease

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. 

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark study that has profoundly influenced our understanding of Alzheimer’s disease by identifying the earliest changes in brain structure and function that signal its onset and progression.

Sports and Health Research Program

The Sports and Health Research Program (SHRP) sought to help accelerate research that enhances the health of athletes at all ages and levels, and to extend the research’s impact beyond the playing field to benefit others in the general population, including members of the military.

Sports and Health Research Program: Pilot Projects on Sports-Related Brain and Spinal Cord Injury Research

Pilot Projects on Sports-Related Brain and Spinal Cord Injury Research was a component of the Sports and Health Research Program (SHRP) that funds pilot projects for research on sports-related traumatic brain injury and spinal cord injury research.

Accelerating Medicines Partnership: Type 2 Diabetes Project

https://www.nature.com/articles/s41586-019-1231-2The Accelerating Medicines Partnership Type 2 Diabetes Project (AMP T2D), is a multi-sector, pre-competitive partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.

Sports and Health Research Program: Chronic Traumatic Encephalopathy and Delayed Effects of Traumatic Brain Injury

Chronic Traumatic Encephalopathy and Delayed Effects of Traumatic Brain Injury was a component of the Sports and Health Research Program. It sought to more fully characterize the neuropathology associated with chronic traumatic encephalopathy (CTE) and delayed effects of traumatic brain injury through systematic, rigorous and collaborative studies of post-mortem biospecimens.

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systemic Lupus Erythematosus & Related Autoimmune Disorders

Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus & Related Autoimmune Disorders is an initiative of the Accelerating Medicines Partnership (AMP), which is a multi-sector, pre-competitive  partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.